Who
Allison Hagerman
Chief Technology Officer
Company insider
Files Form 4 as: Chief Technology Officer, Oncolytics Biotech.
In numbers
- Trades disclosed
- 4
- Buys
- 1
- Sells
- 0
- Bought
- $17K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Feb 2026
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ONCY Oncolytics Biotechoption or derivative · Biotechnology | SEC FORM 4 Code A | —260,000 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $8,29810,000 at $0.8298 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ONCY Oncolytics BiotechBiotechnology | SEC FORM 4 Bought | $8,30010,000 at $0.83 | filing |
News
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 9.8% – Still a Buy?ONCY · dailypolitical.com · 16 Oct 2026Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentONCY · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Allison Hagerman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.